Pharmaceuticals
Clinical Outcomes of Switching from Prostaglandin Analogs to Omidenepag Isopropyl in Primary Open-Angle Glaucoma and Glaucoma Suspect Patients with Prostaglandin-Associated Periorbitopathy: A Prospective, Multicenter Study
By Jin Wook Jeoung, Jong Jin Jung, Hae-Young Lopilly Park and 3 others.
Abstract
Background/Objectives: Prostaglandin-associated periorbitopathy (PAP) is a common treatment-related burden of prostaglandin analog (PGA) therapy that may compromise long-term glaucoma management. This study evaluated improvement in PAP and changes in intraocular pressure (IOP) after switching from PGAs to omidenepag isopropyl.